Cargando…

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes

OBJECTIVE: Clinical trials suggest that SGLT2 inhibitors reduce the risk of cardiovascular mortality in patients with type 2 diabetes, however the mechanism is unclear. Our objective was to test the hypothesis that blood pressure reduction is one potential mechanism underlying the observed improveme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benham, Jamie L., Booth, Jane E., Sigal, Ronald J., Daskalopoulou, Stella S., Leung, Alexander A., Rabi, Doreen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892922/ https://www.ncbi.nlm.nih.gov/pubmed/33659605 http://dx.doi.org/10.1016/j.ijcha.2021.100725

Ejemplares similares

Sex differences in the efficacy of antihypertensive treatment in preventing cardiovascular outcomes and reducing blood pressure: protocol for a systematic review and meta-analysis
por: Gasbarrino, Karina, et al.
Publicado: (2020)

Prevalence of and risk factors for excess weight gain in pregnancy: a cross-sectional study using survey data
por: Benham, Jamie L., et al.
Publicado: (2021)

ODP409 Exercise Increases Microbiota Diversity in Women with Polycystic Ovary Syndrome: A Secondary Analysis of a Pilot Randomized Controlled Trial
por: Benham, Jamie, et al.
Publicado: (2022)

Comparative Success of Recruitment Strategies for an Exercise Intervention Trial Among Women With Polycystic Ovary Syndrome: Observational Study
por: Benham, Jamie L, et al.
Publicado: (2021)

MON-042 The Effect of Exercise Training on Reproductive and Cardiometabolic Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial
por: Benham, Jamie L, et al.
Publicado: (2020)

Exercise training and reproductive outcomes in women with polycystic ovary syndrome: A pilot randomized controlled trial
por: Benham, Jamie L., et al.
Publicado: (2021)

Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis
por: Butalia, Sonia, et al.
Publicado: (2011)

Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
por: Pinto, Lana Catani, et al.
Publicado: (2015)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
por: Mavrakanas, Thomas A., et al.
Publicado: (2023)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
por: Qiu, Mei, et al.
Publicado: (2020)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis
por: Zou, Cai-Yan, et al.
Publicado: (2019)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
por: Vargas-Delgado, Ariana P., et al.
Publicado: (2023)

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
por: Barreto, Joaquim, et al.
Publicado: (2023)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
por: McGuire, Darren K., et al.
Publicado: (2020)

Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis
por: Li, Ning, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

Household Air Pollution and Blood Pressure, Vascular Damage, and Subclinical Indicators of Cardiovascular Disease in Older Chinese Adults
por: Kanagasabai, Thirumagal, et al.
Publicado: (2021)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
por: Cardoso, Rhanderson, et al.
Publicado: (2021)

Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis
por: Rivera, Frederick Berro, et al.
Publicado: (2023)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
por: Tsampasian, Vasiliki, et al.
Publicado: (2021)

Effect of Maternal Obstructive Sleep Apnea-Hypopnea on 24-Hour Blood Pressure, Nocturnal Blood Pressure Dipping and Arterial Stiffness in Hypertensive Disorders of Pregnancy
por: Panyarath, Pattaraporn, et al.
Publicado: (2021)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
por: Lin, Chu, et al.
Publicado: (2021)

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis
por: Drexel, Heinz, et al.
Publicado: (2019)

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
por: Inzucchi, Silvio E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_18ehm8tbm1nm90kirbtltn41ne